[TNF-blockade--new strategy in difficult-to-treat asthma].
Dahlén
Sven-Erik
SE
Centrum för allergiforskning, Karolinska institutet, Stockholm. sven-erik.dahlen@ki.se
Millinger
Eva
E
Skedinger
Maria
M
Zetterström
Olle
O
Dahlén
Barbro
B
D018927:Anti-Asthmatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy*; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D018927:Anti-Asthmatic Agents; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D007155:Immunologic Factors; D014409:Tumor Necrosis Factor-alpha